Tundra Space

Tundra Space

Book DemoDirectoryLog InSign Up

Clinical Research Directory

Browse clinical research sites, groups, and studies.

SitesGroupsStudies
Back to Studies
RECRUITING
NCT05461430

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Sponsor: Travera Inc

View on ClinicalTrials.gov

Summary

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Official title: Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

200

Start Date

2022-07-15

Completion Date

2028-07

Last Updated

2025-09-15

Healthy Volunteers

No

Conditions

Pleural Effusion, MalignantAscites, MalignantCarcinomaCarcinoma, HepatocellularCarcinoma, Renal CellCarcinoma, RenalCarcinoma, Small CellCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic DuctalCarcinoma, NeuroendocrineCarcinoma, ThymicCarcinoma, PancreaticCarcinoma BreastCarcinoma, OvarianCarcinoma BladderCarcinoma of Unknown PrimaryCarcinoma of the Head and NeckCarcinoma of the OropharynxCarcinoma of the LarynxCarcinoma of the BladderCarcinoma of EsophagusCarcinoma of the NasopharynxCarcinoma of the PenisCarcinoma of the CervixCarcinoma of the AnusCarcinoma of the VulvaCarcinoma of the AppendixCarcinoma of the Oral CavityCholangiocarcinomaMelanomaMesotheliomaPancreatic Cancer

Locations (1)

xCures

Oakland, California, United States